Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otaplimastat - Shin Poong Pharmaceutical

Next Previous
Drug Profile

Otaplimastat - Shin Poong Pharmaceutical

Alternative Names: SP-8203; SP-8203 hydrochloride; SP8203HCL

Latest Information Update: 14 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shin Poong Pharmaceutical
  • Class Amides; Amines; Neuroprotectants; Quinazolines; Small molecules
  • Mechanism of Action Reactive oxygen species inhibitors; Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ischaemic stroke

Most Recent Events

  • 28 Oct 2024 Shin Poong Pharmaceutical plans a phase III trial for Ischaemic stroke (Adjunctive treatment) (IV), in December 2024 (NCT06660719)
  • 19 Oct 2020 Shin Poong Pharmaceutical completes a phase IIb trial for Stroke (Adjuvant treatment) in South Korea (NCT04479449)
  • 01 May 2016 Phase-II clinical trials in Ischaemic stroke (Adjunctive treatment) in South Korea (IV) (NCT02787278)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top